The UAE's Ministry of Health and Prevention (MOHAP) has initiated a Sinopharm “immune bridge study” for children aged three to 17 years.
12 June 2021, 12:00 AM
30 June 2021, 12:00 AM
As a significant next step in combating the pandemic and providing protection for all members of the community, UAE’s Ministry of Health and Prevention (MOHAP) has initiated a Sinopharm immune bridge study for children aged 3 to 17 years.
Abu Dhabi Department of Health —(DoH) has approved the study to be conducted, under the supervision of MOHAP. The DoH will implement all applicable medical protocols in accordance with the highest international standards and practices.
The study aims to monitor the immune response to the vaccine in 900 children of different nationalities in preparation to vaccinate children in the near future.
The UAE is the first country in the Middle East and North Africa region to conduct a study of the vaccine’s effectiveness for this age group. Other vaccine manufacturing countries, such as China, the United States, United Kingdom and India, have also begun conducting clinical trials for this group over the past few months.
The children will participate with the full consent of their parents, and be closely monitored, with their safety the most important concern of the study. Parents and children will be given details and support at every step of the process.
“As more and more people are vaccinated in the UAE, we want to make sure that our children are able to receive the vaccine safely. This is why when we designed the Sinopharm immune bridge study, we focused on ensuring all care is given to our young volunteers throughout the journey. We want both children and parents to understand every step of the process and also to know that we will be with them, supporting them, answering every question they may have, at any time,” said Dr Nawal Al Kaabi, chairwoman of the National COVID-19 Clinical Management Committee, who is leading the study.